Get the Stockscreener App
24.63
0.44%
-0.11
After Hours:
24.63
Arvinas Inc stock is traded at $24.63, with a volume of 348.64K.
It is down -0.44% in the last 24 hours and down -5.85% over the past month.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
See More
Previous Close:
$24.74
Open:
$24.63
24h Volume:
348.64K
Relative Volume:
0.51
Market Cap:
$1.70B
Revenue:
$71.30M
Net Income/Loss:
$-354.80M
P/E Ratio:
-4.4061
EPS:
-5.59
Net Cash Flow:
$-356.00M
1W Performance:
+1.69%
1M Performance:
-5.85%
6M Performance:
-40.33%
1Y Performance:
+25.41%
1-Day Range:
$24.27
$25.22
1-Week Range:
$23.64
$25.22
52-Week Range:
$13.57
$53.08
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
An analyst sees good growth prospects for Arvinas Inc (ARVN) - SETE News
Perceptive Advisors LLC Decreases Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
(ARVN) Trading Signals - Stock Traders Daily
Wall Street SWOT: Arvinas stock rides wave of protein degradation promise - Investing.com
Renaissance Technologies LLC Has $7.33 Million Stake in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Magnetar Financial LLC Purchases 22,245 Shares of Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Magnetar Financial LLC Purchases 22,245 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Shares Purchased by Edgestream Partners L.P. - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Shares Bought by Seven Eight Capital LP - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Stake Raised by Seven Eight Capital LP - MarketBeat
1,574 Shares in Arvinas, Inc. (NASDAQ:ARVN) Acquired by Quest Partners LLC - Defense World
Ratios Uncovered: Breaking Down Arvinas Inc (ARVN)’s Trailing Twelve Months Metrics - The Dwinnex
Technical analysis of Arvinas Inc (ARVN) stock chart patterns - US Post News
Rhumbline Advisers Raises Position in Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Victory Capital Management Inc. Has $1.44 Million Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Federated Hermes Inc. Has $4.69 Million Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Sees Large Growth in Short Interest - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Arizona State Retirement System Decreases Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Principal Financial Group Inc. Sells 2,217 Shares of Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Arvinas (NASDAQ:ARVN) shareholders have endured a 74% loss from investing in the stock three years ago - Yahoo Finance
Arvinas, Inc. (NASDAQ:ARVN) Shares Sold by TD Asset Management Inc - MarketBeat
TD Asset Management Inc Sells 107,800 Shares of Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Shares Sold by Los Angeles Capital Management LLC - Defense World
Bank of New York Mellon Corp Increases Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Position Boosted by Bank of New York Mellon Corp - Defense World
Vanguard Group Inc's Strategic Acquisition of Arvinas Inc Shares - Yahoo Finance
Arvinas (NASDAQ:ARVN) Given Overweight Rating at Cantor Fitzgerald - Defense World
Numerous Arvinas Insiders Sold Stock: Not A Positive Omen - Simply Wall St
Critical Insights From Arvinas Analyst Ratings: What You Need To Know - Benzinga
Arvinas (NASDAQ:ARVN) Given Overweight Rating at Cantor Fitzgerald - MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Grows Stock Position in Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Shares Bought by Candriam S.C.A. - Defense World
Candriam S.C.A. Boosts Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Shares Bought by Allspring Global Investments Holdings LLC - Defense World
Arvinas, Inc. (ARVN): This Small-Cap Healthcare Stock Is A Good Buy Right Now - MSN
Arvinas, Inc. (ARVN): This Small-Cap Healthcare Stock Is A Good Buy Right Now - Insider Monkey
Arvinas, Inc. (ARVN): This Small-Cap Healthcare Stock Is A Good Buy Right Now - Yahoo Finance
Arvinas (NASDAQ:ARVN) Shares Down 3.1% - MarketBeat
10 Best Small-Cap Healthcare Stocks To Buy Now - Insider Monkey
(ARVN) Proactive Strategies - Stock Traders Daily
Arvinas, Inc. (NASDAQ:ARVN) Short Interest Up 11.4% in August - MarketBeat
Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains? - MSN
Panagora Asset Management Inc. Purchases 93,568 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas to Participate in Upcoming Investor Conferences - GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences - Yahoo Finance
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
New Haven’s new life sciences tower, 101 College St., loses major tenant - Hartford Business Journal
It's your town. Read all about it. - New Haven Independent
New Haven biotech company scraps plans to relocate to 101 College Street - Greenwich Time
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):